Skip to main content
. 2016 Jun 6;48(6):536–543. doi: 10.1093/abbs/gmw031

Figure 1.

Figure 1.

Schematic diagram and purification of Physarum myosin hybrid constructs (A) Schematic diagram of Physarum myosin hybrid constructs. (B) SDS-PAGE (12.5%) of purified Physarum myosin hybrid constructs associated with LCs of Physarum and/or scallop myosins. Lane M, molecular weight marker; lane 1, Ph·HC/PhRLC/PhELC; lane 2, Ph·HC/ScRLC/ScELC; lane 3, Ph·HC/ScRLC/PhELC; lane 4, Ph·HC/PhRLC/ScELC. (C) SDS-PAGE (12.5%) of purified myosin mutant Ph·HC/PhRLC/PhELC-3A and hybrid myosin mutant Ph·HC/ScRLC/PhELC-3A. Lane M, molecular weight marker; lane 5, Ph·HC/PhRLC/PhELC-3A; lane 6, Ph·HC/ScRLC/PhELC-3A. (D) Glycerol PAGE showing LCs of expressed Physarum hybrid myosin Ph·HC/PhRLC/ScELC (a), expressed Physarum hybrid myosin Ph·HC/ScRLC/ScELC (b), Physarum myosin (c), and purified scallop myosin (d). (E) Glycerol PAGE showing LCs of expressed Physarum myosin mutants of Ph·HC/PhRLC/PhELC-3A (e) and hybrid myosin mutant Ph·HC/ScRLC/PhELC-3A (f).